FDA
-
-
-
-
-
-
-
FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer
-
-
-
-
-
-
-
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
-
-
-
-
-
-
-
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
-
-
-
-
-
-
-
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
-
-
-
-
-
-
-
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
-
-
-
-
-
-
-
Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
-
327,072 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

